Bioporto: New EVP and CFO Niels Høy Nielsen
Bioporto a diagnostic innovator with a potential game-changing NGAL biomarker for AKI.
The company today announced the appointment of a new CFO Niels Høy Nielsen. The new CFO will start august 1. 2024.
Earlier this year the company announced a new strategy and with the latest appointment of a President and CEO for Bioporto Inc. Mr. Jeffrey N. Haas, appointment of EVP and CLO Gry Louise Husby Larsen and EVP and CFO Niels Høy Nielsen the leaderteam is settled and ready to deliver on the strategy.
Read full announcement:CFO announcement
We host Bioporto at our Life Science seminar June 4th 2024 - sign up here: Life Science seminar
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 3:05 PM 30-05-2024.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
BioPorto
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Lue lisää yhtiösivulla